Kiora Pharmaceuticals (KPRX) investor relations material

Executive summary

• Clinical-stage specialty pharmaceutical company advancing KIO-301 and KIO-104 in clinical trials, with KIO-301 targeting vision restoration and KIO-104 for retinal inflammation.

• Enrollment in the Phase 2 ABACUS-2 study of KIO-301 is progressing rapidly, with expanded trial sites and strong patient demand.

• ABACUS-1 trial results for KIO-301 were published in Nature Medicine, validating its potential for vision restoration in late-stage retinitis pigmentosa.

• Entered strategic agreements with Théa Open Innovation (TOI) and Senju Pharmaceutical, securing upfront payments and potential milestone/royalty revenues.

• Operational runway extends into late 2028, supported by recent strategic equity financing.

Financial highlights

• Net loss for Q1 2026 was $2.42 million, compared to $2.19 million in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $11.0 million; short-term investments were $2.9 million, totaling $13.9 million.

• Raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end.

• Research and development expenses were $2.1 million (before $1.2 million in reimbursable expenses), down from $2.5 million (before $2.0 million in reimbursable expenses) year-over-year.

• Revenue recognized in Q1 2024 from TOI license agreement was $16 million; no significant revenue in Q1 2026.

Outlook and guidance

• Sufficient cash and investments, including $5 million from an April 2026 private placement, expected to fund operations into late 2028.

• Focus remains on advancing clinical programs and preparing for potential global registration studies and commercialization.

• Future financing may be needed for expanded development or commercialization efforts.

• Ongoing and planned clinical trials for KIO-301 and KIO-104 are expected to drive future milestones and potential revenue.